Core Insights - Qiagen reported revenue of $496.35 million for the quarter ended June 2024, reflecting a year-over-year increase of 0.3% and surpassing the Zacks Consensus Estimate by 0.45% [1] - Earnings per share (EPS) for the quarter was $0.55, up from $0.53 in the same quarter last year, exceeding the consensus EPS estimate by 5.77% [1] Revenue Performance by Product Groups - Diagnostic solutions - QIAstat-Dx: Revenue of $24 million, a year-over-year increase of 14.3%, but below the average estimate of $24.37 million [3] - Diagnostic solutions - QuantiFERON: Revenue of $115 million, a year-over-year increase of 10.6%, exceeding the average estimate of $113.62 million [4] - Sample technologies: Revenue of $164 million, a year-over-year decrease of 0.6%, surpassing the average estimate of $160.34 million [5] - Diagnostic solutions: Revenue of $185 million, a year-over-year increase of 4.5%, closely matching the average estimate of $185.03 million [6] - Diagnostic solutions - NeuMoDx: Revenue of $7 million, a significant year-over-year decrease of 36.4%, falling short of the average estimate of $9.32 million [7] - Genomics / NGS: Revenue of $58 million, a year-over-year decrease of 9.4%, below the average estimate of $61.95 million [8] - PCR / Nucleic acid amplification: Revenue of $76 million, a year-over-year increase of 2.7%, exceeding the average estimate of $69.68 million [9] - Other: Revenue of $14 million, a year-over-year decrease of 6.7%, below the average estimate of $14.97 million [9] Revenue by Segment - Molecular Diagnostics: Revenue of $266 million, a year-over-year increase of 2.3%, surpassing the average estimate of $262.74 million [10] - Life Sciences: Revenue of $230 million, a year-over-year decrease of 2.1%, slightly below the average estimate of $231.79 million [11] - Diagnostic solutions - Other: Revenue of $39 million, a year-over-year decrease of 2.5%, exceeding the average estimate of $38.67 million [12] Stock Performance - Qiagen's shares have returned +9.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.4% change [12]

Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.77%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%. Over the last four quarters, the ...

Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supportin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Qiagen (QGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estima ...

QIAGEN N.V. (QGEN) is poised to grow in the upcoming quarters, backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. In addition, sound financial stability instills optimism. In the past year, this Zacks Rank #2 (Buy) stock has declined 10.4% compared with a 4% decrease in the industry. The S&P 500 composite has witnessed a 23.4% rise in the said time frame. Let's delve deeper. Progress in T ...

Qiagen (QGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where t ...

Core Insights - QIAGEN N.V. has announced a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance forensic applications and human identification using next-generation sequencing (NGS) technologies [1][2] - The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) through advanced DNA technologies [3][6] Partnership Details - The collaboration will utilize QIAGEN's MiSeq FGx sequencing system, ForenSeq Kintelligence kits, and the ForenSeq Kintelligence HT System [1] - Snow Lab, in conjunction with Ohkomi Forensics, will establish the first indigenous-owned DNA database to identify remains of 95 African American individuals found in Sugar Land, TX [4][5] Technology and Market Potential - QIAGEN's NGS and forensic investigative genetic genealogy (FIGG) technologies can process severely degraded or contaminated DNA, which is common in forensic cases [6] - The global human identification market is projected to grow from $0.8 billion in 2024 to $1.3 billion by 2029, representing a compound annual growth rate (CAGR) of 10.7% [7] Recent Developments - In June 2024, QIAGEN launched 35 new digital PCR Microbial DNA Detection Assays for its QIAcuity platform, enhancing its microbial research capabilities [9] - QIAGEN's QIAstat-Dx Gastrointestinal Panel 2 received FDA clearance for clinical use, marking a significant advancement for the company in the U.S. market [10] Stock Performance - Over the past year, QIAGEN's shares have declined by 13.4%, compared to a 7.6% decline in the industry [11]

Missoula, Montana, and Venlo, the Netherlands, July 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics. Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System. "Our collaboration with ...

Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2492 Conference ID: 8081810 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. About QIAGEN Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Access the audio webcast - Click here: Access Webcast ...

QIAGEN N.V. (QGEN) recently lauded the new guidelines in the United States that recommend screening atrisk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QuantiFERON-TB Gold Plus (QFT-Plus). The latest guidelines from the American Academy of Pediatrics (AAP) highlight testing for TB with modern interferon-gamma release assays (IGRAs). With this development, the company aims for its market-leading QFT-Plus to be a gold standard for blood-based tuberculosis d ...